Scientific Advisory Board
Comprised of leading experts representing the forefront of the life sciences industry, our Scientific Advisory Board provides insight and guidance for evaluating opportunities and development of new products.
Dennis Harris, Ph.D.
Co-Founder of IntegenX
Chief Scientific Officer
Dennis Harris, Ph.D.
Dr. Dennis Harris is a co-founder of IntegenX and is an experienced executive who has spent the majority of his career developing and implementing business strategies for life science companies to maximize their research and development efforts and to enhance their ability to bring innovation to customers. In his various roles, he has initiated and led successful portfolio acquisitions and negotiated technology collaborations. Prior to IntegenX, he served as Chief Scientific Officer at Millipore since 2006. He was Vice President and Chief Scientific Officer at Serologicals Corporation from 2004 to 2006 and Executive Vice President of Research and Development at Vitra Bioscience from 2002 to 2003. He served as Senior Vice President at Aclara Biosciences, Inc., a developer of microfluidics and gene and protein analysis technologies. Prior to Aclara, he held positions of increasing responsibility at Amersham Pharmacia Biotech (now part of GE Healthcare) including Vice President of Research and Development. Dr. Harris has extensive background in DNA sequencing and laboratory automation systems.
Dr. Harris currently serves on the board of directors for IntegenX, and also serves on the board of directors for Biolog, Inc..
Dr. Harris earned his B.SC. Hons. in Biochemistry and Ph.D. from the University of Sussex, England. He has authored 17 papers.
Richard A. Mathies, Ph.D.
Dr. Richard Mathies is a co-founder of IntegenX. His work in the area of biotechnology and the Human Genome Project led to the development of new high-speed, high-throughput DNA analysis technologies such as capillary array electrophoresis and energy transfer (ET) fluorescent dye labels for DNA sequencing and analysis. In particular, his development of ET fluorescent labels was critical to the early completion of the Human Genome sequence. He also pioneered the development of microfabricated capillary electrophoresis devices and microfabricated integrated sample preparation and detection methods for lab-on-a-chip analysis systems that are being applied to DNA sequencing, diagnostics, forensics, pathogen detection and space exploration. Dr. Mathies has been Professor of Chemistry at the University of California at Berkeley since 1976, and was appointed in 2008 as Dean of the College of Chemistry and the Gilbert Newton Lewis Professor. He is a co-founder and Director of the Center for Analytical Biotechnology at UC Berkeley. He also serves on the scientific advisory boards of Affymetrix, Allopartis, and NanoString.
Dr. Mathies is author of over 380 publications and 35 patents on photochemistry, photobiology, bioanalytical chemistry and genome analysis technology.
Dr. Mathies holds a Bachelor’s degree in Chemistry from the University of Washington. He earned his M.S. and Ph. D. in Physical Chemistry at Cornell University from Andreas Albrecht. He completed two years of postdoctoral study as a Helen Hay Whitney Postdoctoral Fellow at Yale with Lubert Stryer.
Mostafa Ronaghi, Ph.D.
Senior Vice President and
Chief Technology Officer, Illumina, Inc.
Mostafa Ronaghi, Ph.D. 
Dr. Mostafa Ronaghi joined Illumina in 2008 following their acquisition of Avantome, a sequencing technology start-up that he co-founded in 2007. From 2002 to 2008, Dr. Ronaghi was a principal investigator at the Stanford Genome Technology Center where he focused on developing molecular diagnostic applications. He is an experienced entrepreneur, having co-founded four successful life sciences companies. In 2004, he co-founded NextBio, which develops and markets a discovery platform for life science data, and serves as chairman of their Scientific Advisory Board. In 2001, he co-founded ParAllele BioScience, which developed highly multiplexed technology for genetic testing and was acquired by Affymetrix in 2005. In 1997, he co-founded Pyrosequencing AB (renamed Biotage), and led the company to a successful initial public offering in 2000 on the Stockholm Stock Exchange.
Dr. Ronaghi also serves on the board of directors of NextBio and Aurora Biofuels.
Dr. Ronaghi earned his Ph.D. from the Royal Institute of Technology in Sweden. He holds more than 20 pending and issued patents and has written over 50 peer-reviewed publications in journals and books.
Allan Tereba, Ph.D. 
Dr. Allan Tereba has made significant contributions in the area of forensics over the last decade. He helped develop the first 16-locus single amplification multiplex currently used in DNA identification, and he created and patented an automatable chemistry for obtaining pure DNA from highly contaminated forensic casework samples. This chemistry also delivered a constant amount of DNA from various database samples, eliminating the need for DNA quantification. Using this chemistry in collaboration with the Virginia Division of Forensic Sciences, he developed the first successful high-throughput, automated DNA purification system for casework samples. Additional chemistries and hardware were developed for high throughput processing of both casework and database samples at all stages of the process.
Dr. Tereba currently consults with various forensic groups. He was formerly at Promega Corporation where he developed nucleic acid synthesis and signal transduction products and later joined their forensic group. Dr. Tereba was also a faculty member in the Department of Virology and Molecular Biology at St. Jude Children’s Research Hospital, where he studied the chromosomal location of endogenous retroviruses and oncogenes and the chromosomal abnormalities and amplification mechanism of the N-myc oncogene associated with neuroblastoma.
Dr. Tereba earned his Bachelor’s degree in Chemistry at Indiana University and his Ph. D. in Biochemistry at the University of Washington. He spent two years studying retroviruses as a Damon Runyon Postdoctoral Fellow with Dr. Peter Vogt at the Keck School of Medicine at the University of Southern California.
Lloyd J. Whitman, Ph.D.
Deputy Director,
Center for Nanoscale Science and Technology
Lloyd J. Whitman, Ph.D. 
Dr. Lloyd J. Whitman joined the Center for Nanoscale Science and Technology in 2008 as its first Deputy Director. Previously, Dr. Whitman was Head of the Surface Nanoscience and Sensor Technology Section at the Naval Research Laboratory (NRL), where he led a multidisciplinary research team of biologists, chemists, engineers, and physicists working at the nexus of nanoscience, biotechnology, and microsystems. He directed projects studying semiconductor, organic, and biomolecular nanostructures, their use in novel functional surfaces, and their integration into biosensor systems and optoelectronic devices for national security and defense applications. In addition to leading research at NRL, Dr. Whitman helped manage nanotechnology and biodefense programs for a number of agencies within the Department of Defense. He has assisted the National Science and Technology Council in formulating National Nanotechnology Initiative goals for National Defense and Security, and served as a Science Advisor to the Special Assistant to the Secretary of Defense for Chemical and Biological Defense and Chemical Demilitarization Programs.
Dr. Whitman joined the research staff at NRL in 1991 after completing a National Research Council Postdoctoral Fellowship at the National Institute of Standards and Technology. He has been studying surface nanoscience and sensor technology for over 25 years, with over 140 publications and patents, and numerous media citations and awards.
Dr. Whitman holds a B.S. in Physics with honors, magna cum laude, from Brown University, and M.S. and Ph.D. degrees in Physics from Cornell University.